Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Aquestive Therapeutics, Inc. (AQST)  
$3.36 0.38 (10.04%) as of 4:30 Tue 4/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 33,620,000
Market Cap: 112.96(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.27 - $6.09
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Aquestive Therapeutics is a pharmaceutical company. Co. is developing orally administered products to deliver various molecules using its proprietary technologies, PharmFilm®. Co.'s products within its central nervous system portfolio, focused on epilepsy, include: Sympazan®, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome; and Libervant™, a buccally, or inside of the cheek, administered soluble film formulation of diazepam, used as an alternative to device-dependent rescue therapies, available to patients with refractory epilepsy, which are a rectal gel and nasal sprays.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 158,668
Total Buy Value $0 $0 $0 $151,571
Total People Bought 0 0 0 4
Total Buy Transactions 0 0 0 5
Total Shares Sold 75,000 75,000 75,000 75,000
Total Sell Value $429,685 $429,685 $429,685 $429,685
Total People Sold 1 1 1 1
Total Sell Transactions 2 2 2 2
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 146
  Page 1 of 6  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Schobel Alexander Mark Chief Innovation/Tech Officer   •       –      –    2024-03-15 4 AS $6.00 $300,000 D/D (50,000) 984,476 -33%     
   Jung Cassie SVP, Operations   •       –      –    2024-03-10 4 D $4.88 $5,524 D/D (1,132) 237,754     -
   Wargacki Stephen SVP, Research & Development   •       –      –    2024-03-10 4 D $4.88 $8,233 D/D (1,687) 257,963     -
   Jung Cassie SVP, Operations   •       –      –    2024-03-09 4 D $4.88 $40,504 D/D (8,300) 238,886     -
   Boyd Peter E. See Remark   •       –      –    2024-03-09 4 D $4.88 $40,846 D/D (8,370) 237,628     -
   Barber Daniel President and CEO   •       –      –    2024-03-09 4 D $4.88 $185,137 D/D (37,938) 845,364     -
   Braender Lori J SVP, General Counsel   •       –      –    2024-03-09 4 D $4.88 $51,386 D/D (10,530) 313,231     -
   Wargacki Stephen SVP, Research & Development   •       –      –    2024-03-09 4 D $4.88 $54,993 D/D (11,269) 259,650     -
   Schobel Alexander Mark Chief Innovation/Tech Officer   •       –      –    2024-03-09 4 D $4.88 $28,768 D/D (5,895) 1,034,476     -
   Toth A Ernest Jr SVP, Chief Financial Officer   •       –      –    2024-03-09 4 D $4.88 $57,120 D/D (11,705) 248,295     -
   Schobel Alexander Mark Chief Innovation/Tech Officer   •       –      –    2024-03-08 4 AS $5.19 $129,685 D/D (25,000) 1,040,371 -17%     
   Toth A Ernest Jr SVP, Chief Financial Officer   •       –      –    2024-03-07 4 A $0.00 $0 D/D 120,000 260,000     -
   Schobel Alexander Mark Chief Innovation/Tech Officer   •       –      –    2024-03-07 4 A $0.00 $0 D/D 82,500 1,065,371     -
   Boyd Peter E. See Remark   •       –      –    2024-03-07 4 A $0.00 $0 D/D 86,250 245,998     -
   Wargacki Stephen SVP, Research & Development   •       –      –    2024-03-07 4 A $0.00 $0 D/D 112,500 270,919     -
   Kraus Carl N Chief Medical Officer   •       –      –    2024-03-07 4 A $0.00 $0 D/D 112,500 262,500     -
   Barber Daniel President and CEO   •       –      –    2024-03-07 4 A $0.00 $0 D/D 242,600 883,302     -
   Braender Lori J SVP, General Counsel   •       –      –    2024-03-07 4 A $0.00 $0 D/D 135,000 323,761     -
   Jung Cassie SVP, Operations   •       –      –    2024-03-07 4 A $0.00 $0 D/D 101,250 247,186     -
   Kraus Carl N Chief Medical Officer   •       –      –    2023-08-09 4 A $0.00 $0 D/D 150,000 150,000     -
   Wargacki Stephen SVP, Research & Development   •       –      –    2023-03-10 4 D $0.79 $1,572 D/D (1,981) 158,419     -
   Jung Cassie SVP, Operations   •       –      –    2023-03-10 4 D $0.00 $0 D/D (1,365) 145,936     -
   Barber Daniel President and CEO   •       –      –    2023-03-09 4 A $0.00 $0 D/D 447,000 640,702     -
   Schobel Alexander Mark Chief Innovation/Tech Officer   •       –      –    2023-03-09 4 A $0.00 $0 D/D 100,000 982,871     -
   Jung Cassie SVP, Operations   •       –      –    2023-03-09 4 A $0.00 $0 D/D 110,000 146,747     -
  146 Records found
  1  2  3  4  5  6   
  Page 1 of 6
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us